2 results match your criteria: "Chinese Academy of Medical Sciences and Peking Union Medical College (PUMC)[Affiliation]"
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma.
Clin Cancer Res
October 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (PUMC), Tianjin, China.
Purpose: Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- and T-cell lymphomas, but as a drug class, these agents have frequently been observed to have tolerability limitations. Next-generation agents that improve the tolerability while maintaining efficacy are desirable.
View Article and Find Full Text PDFIncidence of adverse cutaneous drug reactions in 22,866 Chinese inpatients: a prospective study.
Arch Dermatol Res
November 2015
Department of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital (PUMCH), Beijing, 100730, China.
Cutaneous adverse drug reactions (ADRs) are common. However, no prospective study assessing cutaneous ADRs is available for Chinese populations. This study aimed to assess the incidence, manifestations, causative drugs, and other factors related to cutaneous ADRs.
View Article and Find Full Text PDF